The Greenville Hospital System Cancer Institute and Greenville-based Kiyatec have partnered to provide cancer patients with the diagnostic testing they need to make informed health decisions. The first of these tests to be available is one that can indicate ovarian cancer patients’ future response to chemotherapy before undergoing treatment with up to 93% accuracy, according to a news release.
As the flagship clinical partner of Kiyatec, GHS Cancer Institute patients will be the first to receive the opportunity to benefit from these tests through clinical studies initially applicable to all ovarian cancer patients. Through the partnership, Kiyatec will expand the test offerings to patients with other cancers within the coming year, according to the release.
“Human cells are as unique as the patients themselves, so you really need to see the way those cells interact with given drugs to know for certain what treatment will work,” said Matthew Gevaert, CEO of Kiyatec, in the release. “By placing each patient’s cancer cells in conditions that mimic the actual human body, we can drill down to drug effect on the cellular level and establish the connection between the results we see in the lab and the response we hope to see in the patients.”